Reset filter
Keywords
On-Study Form ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

294 Search results.
Relevance Rating New first Old first

CALGB 50901 Bone Marrow, Liver, & Spleen Evaluation Form

- 8/28/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Bone Marrow Evaluation, Liver and Spleen Evaluation
CALGB 50901 Bone Marrow, Liver, & Spleen Evaluation Form Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F53BA1C-E73F-7A0D-E040-BB89AD43616B

E5202 Colon Cancer On-Study Form NCT00217737

- 7/8/15 - 1 form, 9 itemgroups, 33 items, 1 language
Itemgroups: Header, Patient demographics, Data amendment, Baseline Evaluation, Pathologic Staging, CEA, Disease Description, Biological Markers, Comments
E5202 Colon Cancer On-Study Form NCT00217737 Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=EF21AC34-1C36-1B9F-E034-0003BA3F9857

E2805 Renal Cell Carcinoma On-Study Form NCT00326898

- 9/20/21 - 1 form, 9 itemgroups, 50 items, 1 language
Itemgroups: Header, Data amendment, Patient demographics, History of Disease, Description of Primary Disease, Description of Current Disease, Current Disease Symptoms, MUGA Scanning, Footer Module
E2805 Renal Cell Carcinoma On-Study Form NCT00326898 Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=053ADDEA-1681-66BC-E044-0003BA3F9857

Kidney Cancer NCT01198158 On-Study - CALGB 90802 On-Study Form - 3107346v1.0 - CALGB 90802 On-Study Form

- 1/9/15 - 1 form, 7 itemgroups, 57 items, 1 language
Itemgroups: Header Module, PATIENT DESCRIPTION, SITES OF DISEASE, BASELINE LABORATORY DATA, Urinalysis, PRIOR TREATMENT, Footer Module
CALGB 90802 On-Study Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=88715713-3A23-2D6C-E040-BB89AD433D3B

CALGB: 80203 On-Study

- 7/28/15 - 1 form, 3 itemgroups, 32 items, 1 language
Itemgroups: Header, Patient details, CCRR MODULE
CALGB: 80203 On-Study Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B4C3AD14-5A1C-0716-E034-0003BA12F5E7

GSK Efficacy and safety of Fluticasone on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) NCT01009463 - Week 4

- 4/5/18 - 1 form, 6 itemgroups, 14 items, 1 language
Itemgroups: Subject withdrawal, Pre-Dose Vital Signs, Candidiasis examination, Electronically transferred lab data, Liver Events Assessment, Smoking Status
Study ID: 102871 Clinical Study ID: HZC102871 Study Title:HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01009463 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Pulmonary Disease, Chronic Obstructive Documentation part: Week 4

GSK Efficacy and safety of Fluticasone on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) NCT01009463 - Week 2

- 4/5/18 - 1 form, 6 itemgroups, 14 items, 1 language
Itemgroups: Subject withdrawal, Pre-Dose Vital Signs, Candidiasis examination, Electronically transferred lab data, Liver Events Assessment, Smoking Status
Study ID: 102871 Clinical Study ID: HZC102871 Study Title:HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01009463 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Pulmonary Disease, Chronic Obstructive Documentation part: Week 2

Liver Cancer NCT01015833 On-Study - CALGB 80802 On-Study Form - 2940677v1.0 - CALGB 80802 On-Study Form

- 9/20/21 - 1 form, 6 itemgroups, 49 items, 1 language
Itemgroups: Header Module, Patient Description, Prior Treatment, Required Lab Values, Child Pugh Classification, Footer Module
CALGB 80802 On-Study Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=73B6D8AE-497C-7324-E040-BB89AD43648A

E3A06 Multiple Myeloma On-Study Form NCT01169337

- 6/16/15 - 1 form, 6 itemgroups, 25 items, 1 language
Itemgroups: Header, Data amendment, Disease Description - Initial Diagnosis, Current Clinical Data, Baseline Abnormalities, Comments
E3A06 Multiple Myeloma On-Study Form NCT01169337 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=86CCB2A8-771D-F281-E040-BB89AD432A9E

E1A06 Multiple Myeloma On-Study Form NCT00602641

- 6/16/15 - 1 form, 6 itemgroups, 31 items, 1 language
Itemgroups: Header, Disease Description - Initial Diagnosis, Current Clinical Data, Prior Therapy, Baseline Abnormalities, Comments
E1A06 Multiple Myeloma On-Study Form NCT00602641 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4001ACAE-416E-2CD1-E044-0003BA3F9857

On-Study - Multiple Myeloma - On-Study Form - 2274325v3.0 - Multiple Myeloma - On-Study Form

- 1/9/15 - 1 form, 4 itemgroups, 58 items, 1 language
Itemgroups: CRF Header, Myeloma: Form Administration, Myeloma: Disease Description, Myeloma: Prior Treatment
Multiple Myeloma - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6E1DCBD-670E-54A2-E034-0003BA12F5E7

The Effect of Albiglutide on Cardiac Repolarisation Compared with Placebo 107085 - Liver Biopsy Data: Liver Infections

- 11/20/18 - 1 form, 3 itemgroups, 19 items, 1 language
Itemgroups: Administrative data, Liver Biopsy, J. Liver Infections
Study ID: 107085 Clinical Study ID: GLP107085 Study Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01406262 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial